Also trades as GMAB.
GMAB.CO
Premium GrowerAI neutralGenmab A/S · Healthcare · Denmark · $24.4B cap · $109.6M/day traded
DKK 3,581.00 -2.2% · close 10 Nov · scored 11 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Around its 5 Nov results, analysts cut next year's EPS estimate 4.4%.
As of 11 Nov 2026, the MoatMap Score for Genmab A/S (GMAB.CO) is 69/100, ranked against 25,000+ stocks in 38 markets (Quality 60, Value 26, Momentum 79, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Genmab is a Danish antibody biotech with high-margin royalties, mainly from J&J's Darzalex, and a growing own-product portfolio. It has a strong net cash balance sheet and credible science. However, royalty concentration on Darzalex creates a patent cliff later in the decade, and the value case depends on pipeline and acquisition execution. The available news gives no fresh catalyst.
ABOUT GENMAB A/S
Read
Genmab A/S is an international biotechnology company focused on the creation and development of differentiated antibody therapeutics for cancer and other serious diseases. Its competitive moat lies in its proprietary antibody technology platforms, such as DuoBody and HexaBody, which enable the development of novel and highly effective drug candidates. Genmab is a specialized and innovative biotech firm with a strong pipeline and a proven track record of bringing successful cancer treatments to market through strategic partnerships.
FINANCIAL SUMMARY (DKK)
Reported in USD
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 14.7B | 16.5B | 21.5B | 24.6B | 18.6% | 28.6B | 31.5B | 38.2B | 24.2% |
| EPS (DKK) | 7.00 | 85.82 | 66.61 | 117.50 | 102.36 | 95.5% | 74.71 | 74.38 | 106.65 | 1.6% |
| Shares | — | 65.4M | 65.3M | 63.5M | 61.6M | -5.8% | 61.5M | — | — | — |
| Debt | — | 599.3M | 767.7M | 1.0B | 34.5B | 286.1% | 34.6B | — | — | — |
| Equity | — | 27.4B | 31.6B | 36.8B | 37.2B | 10.7% | — | — | — | — |
| Op CF | — | 4.0B | 7.4B | 7.8B | 7.8B | 25.4% | 5.8B | — | — | — |
| Inv CF | — | -2.8B | -1.3B | -10.0B | -37.3B | — | — | — | — | — |
| Fin CF | — | -801.8M | -613.0M | -3.9B | 31.6B | — | — | — | — | — |
Above its 200-day average and 9% below its 52-week high.
Swung more than 58% of stocks we rank over the past year (volatility 47% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GMAB.CO are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| GMAB.CO | Genmab A/S(you) | $24.4B | 69 |
| ALK-B.CO | ALK-Abelló A/S | $8.1B | 75 |
| ASND | Ascendis Pharma A/S | $16.0B | 47 |
| ZEAL.CO | Zealand Pharma A/S | $2.2B | 70 |
| BAVA.CO | Bavarian Nordic A/S | $2.8B | 98 |
| GUBRA.CO | Gubra A/S | $711M | 32 |
| SANION.ST | Saniona AB (publ) | $153M | 79 |
| COLO-B.CO | Coloplast A/S | $16.4B | 86 |
| DEMANT.CO | Demant A/S | $11.3B | 80 |
| GN.CO | GN Store Nord A/S | $2.4B | 66 |
Peer medians: ROE 15.9% · P/E 14.3x · Gross margin 82.1%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.